503261328 04/13/2015

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3307946

SUBMISSION TYPE:		NEW ASSIGNMENT			
NATURE OF CONVEYANCE:		ASSIGNMENT			
CONVEYING PARTY D	ΑΤΑ	·			
		Name			Execution Date
THOMAS ANDREW WY	'NN				03/11/2015
CHRISTOPHER P. HEN	ICKEN		1		03/11/2015
RECEIVING PARTY DA	ТА				
Name:	ALKERMES PHARMA IRELAND LIMITED				
Street Address:	CONNAUGHT HOUSE, 1 BURLINGTON ROAD				
City:	DUBLIN				
	IRELAND				
State/Country:	IRELA	ND			
State/Country: Postal Code:	IRELA	ND			
Postal Code:	4	ND			
Postal Code: PROPERTY NUMBERS	4				
Postal Code: PROPERTY NUMBERS Property Type	4	Number			
Postal Code: PROPERTY NUMBERS	4				
Postal Code: PROPERTY NUMBERS Property Type	4 5 Total: 1	Number	· · · · · · · · · · · · · · · · · · ·		
Postal Code: PROPERTY NUMBERS Property Type Application Number:	4 5 Total: 1	Number			
Postal Code: PROPERTY NUMBERS Property Type Application Number: CORRESPONDENCE D	4 5 Total: 1 0ATA e sent to	Number 14630248 (857)300-4001 o the e-mail address fire	st; if that is uns		
Postal Code: PROPERTY NUMBERS Property Type Application Number: CORRESPONDENCE D Fax Number: <i>Correspondence will b</i> <i>using a fax number, if</i> Phone:	4 5 Total: 1 0ATA e sent to	Number 14630248 (857)300-4001 o the e-mail address fir l; if that is unsuccessfe 8573004000	st; if that is uns ul, it will be sen	nt via US	Mail.
Postal Code: PROPERTY NUMBERS Property Type Application Number: CORRESPONDENCE E Fax Number: Correspondence will b using a fax number, if	4 5 Total: 1 0ATA e sent to	Number 14630248 (857)300-4001 o the e-mail address fir l; if that is unsuccessfu 8573004000 aasmith@lathropgage.c	st; if that is uns ul, it will be sen om, bostonpate	nt via US	Mail.
Postal Code: PROPERTY NUMBERS Property Type Application Number: CORRESPONDENCE E Fax Number: <i>Correspondence will b</i> <i>using a fax number, if</i> Phone: Email:	4 5 Total: 1 0ATA e sent to	Number 14630248 (857)300-4001 o the e-mail address fir l; if that is unsuccessfe 8573004000	st; if that is uns ul, it will be sen om, bostonpate	nt via US	Mail.
Postal Code: PROPERTY NUMBERS Property Type Application Number: CORRESPONDENCE D Fax Number: Correspondence will b using a fax number, if Phone:	4 5 Total: 1 0ATA e sent to	Number 14630248 (857)300-4001 o the e-mail address fir l; if that is unsuccess 8573004000 aasmith@lathropgage.co jlewis@lathropgage.con	st; if that is uns ul, it will be sen om, bostonpate	nt via US	Mail.

ATTORNEY DOCKET NUMBER:	566459: ALT-015			
NAME OF SUBMITTER:	BRIAN C. TRINQUE			
SIGNATURE:	/Brian C. Trinque/			
DATE SIGNED:	04/13/2015			
Total Attachments: 3				
source=Assignment-566459#page1.tif				
source=Assignment-566459#page2.tif				
source=Assignment-566459#page3.tif				

ASSIGNMENT

WHEREAS, We, **Thomas Andrew Wynn** of Lexington, Massachusetts and **Christopher P. Hencken** of Boston, Massachusetts, have invented a certain new and useful invention(s), described in the following patent application:

SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES

U.S. Serial No. 14/630,248, filed February 24, 2015

for which we are about to make or have made application for Patent of the United States; and

WHEREAS, ALKERMES PHARMA IRELAND LIMITED, its principal place of business at Connaught House, 1 Burlington Road, Dublin 4, Ireland, is desirous of acquiring all rights, title and interests in and to said invention, said applications, and in and to any and all Letters Patent which may be granted for or upon said invention and applications in the United States of America and anywhere in the world.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, we, **Thomas Andrew Wynn** and **Christopher P. Hencken**, have sold, assigned and transferred, and by these presents to sell, assign and transfer unto the said **ALKERMES PHARMA IRELAND LIMITED**, the full and exclusive right, title and interest, throughout the world, in, to and under the following:

(a) said invention as fully set forth and described in the specification prepared, and executed by us preparatory to obtaining Letters Patent of the United States therefor;

(b) said applications;

(c) any and all refilings, divisions, continuations and continuations-in-part of said applications;

(d) any and all Letters Patent of the United States of America which may issue from said applications, refilings, divisions, continuations and continuations-in-part;

(e) any and all reissues and reexaminations of said Letters Patent of the United States of America;

1 of 3

PATENT REEL: 035395 FRAME: 0206

(f) any and all applications for Letters Patent upon said invention which may hereafter be filed in any and all countries foreign to the United States of America;

(g) any and all refilings, divisions and continuations of said foreign-filed applications;

(h) all claims, causes of action and damages for past infringement, if any, of said application;

 (i) any and all Letters Patent of countries foreign to the United States of America which may issue from the said foreign-filed applications, refilings, divisions and continuations; and

(j) any and all extensions of, and additions to, said Letters Patent of countries foreign to the United States of America.

We, **Thomas Andrew Wynn** and **Christopher P. Hencken** further agree that upon request we will provide promptly all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to **ALKERMES PHARMA IRELAND**

LIMITED or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

ALL of the above shall be held and enjoyed by said ALKERMES PHARMA IRELAND LIMITED, for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said Letters Patent may be granted, and we do hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.

> PATENT REEL: 035395 FRAME: 0207

2 of 3

This assignment to have effect as of the filing date of February 24, 2015.

Thomas Andrew Wynn Signed in my presence and acknowledged to be an assignment of the application herein above referred to: WITNESS Weltham, MASS Signed At (City/State) CINDY A. SRAGG Notary Public Commonwealth of Massachusetts Name My Commission Expires March 11, 2016 Signature

Date

11 March 2015

Date:

Christópher P. Hencken

Signed in my presence and acknowledged to be an assignment of the application herein above referred to:

WITNESS /State` ioned Name Signature Vanch

CINDY A. SRAGG Notary Public Commonwealth of Massachusetts My Commission Expires March 11, 2016

PATENT REEL: 035395 FRAME: 0208